Eli Lilly reported promising mid-stage trial results for its obesity drug EloraTZP, which produced up to 23.3% weight loss in patients. The company plans to begin phase III trials by the end of 2026 and is working to improve the drug’s tolerability.
The supplied account compares the results with Novo Nordisk’s tirzepatide, but tirzepatide is an Eli Lilly drug, not Novo Nordisk’s.
The results add to competition between the pharmaceutical companies in the growing weight-loss treatment market. Analysts are also assessing Novo Nordisk’s valuation amid uncertainty about long-term growth and looming patent expirations for its key semaglutide products.
Some investor platforms showed increased selling interest in Novo Nordisk after Eli Lilly’s announcement, reflecting concern about changing market dynamics.